ENGLEWOOD, Colo., Feb. 28, 2019 /PRNewswire/ -- Zynex, Inc.
(NASDAQ: ZYXI), an innovative medical technology company
specializing in the manufacture and sale of non-invasive medical
devices for pain management, stroke rehabilitation, cardiac
monitoring and neurological diagnostics, today announced it has
hired Christopher A. Brown as its
Vice President of Sales and Marketing.
Chris Brown has spent his entire
career in sales and marketing in the healthcare industry including
start-ups, venture backed and publicly traded companies. Chris has
in his career held Vice President positions with Safeop Surgical,
Nuvasive/Impulse Monitoring, Intelistaff Healthcare and Steris
Corp/AMSCO. Chris holds a Bachelor's Degree in Business
Administration from Indiana University of
Pennsylvania.
Thomas Sandgaard, CEO, said: "I
am excited to have Chris on board to lead our growing sales
organization covering the market for prescription-strength
electrotherapy for pain management. Not only do we continue to hire
sales reps at a rapid rate, we are now creating an infrastructure
that can handle the volume we anticipate from eventually covering
the entire country with sales reps".
About Zynex
Zynex, founded in 1996, markets and sells its own design of
electrotherapy medical devices used for pain management and
rehabilitation; and the company's proprietary NeuroMove device
designed to help recovery of stroke and spinal cord injury
patients. Zynex is also developing a new blood volume monitor for
use in hospitals and surgery centers. For additional
information, please visit: Zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" or
projections and as such are subject to numerous risks and
uncertainties. The company makes no express or implied
representation or warranty as to the completeness of this
information or, in the case of projections, as to their
attainability or the accuracy and completeness of the assumptions
from which they are derived. Actual results may vary significantly
from the results expressed or implied in such statements. Factors
that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the
need to obtain FDA clearance and CE marking of new products, the
acceptance of new products as well as existing products by doctors
and hospitals, larger competitors with greater financial resources,
the need to keep pace with technological changes, our dependence on
the reimbursement for our products from health insurance companies,
our dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force and other risks
described in our filings with the Securities and Exchange
Commission including the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31,
2018 as well as Forms 10-Q, 8-K and 8-K/A, press releases and
the Company's website.
Contact:
Zynex, Inc.
(303) 703-4906
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-names-new-vice-president-of-sales-and-marketing-300804016.html
SOURCE Zynex